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Approximately 40% of preterm births are preceded by microbial invasion of the
intrauterine space; ascent from the vagina being the most common pathway. Within the
cervical canal, antimicrobial peptides and proteins (AMPs) are important components of
the cervical barrier which help to prevent ascending vaginal infection. We investigated
whether expression of the AMP, human β-defensin-3 (HBD3), in the cervical mucosa of
pregnant mice could prevent bacterial ascent from the vagina into the uterine cavity. An
adeno-associated virus vector containing both theHBD3 gene andGFP transgene (AAV8
HBD3.GFP) or control AAV8 GFP, was administered intravaginally into E13.5 pregnant
mice. Ascending infection was induced at E16.5 using bioluminescent Escherichia coli
(E. coli K1 A192PP-lux2). Bioluminescence imaging showed bacterial ascent into the
uterine cavity, inflammatory events that led to premature delivery and a reduction in pups
born alive, compared with uninfected controls. Interestingly, a significant reduction in
uterine bioluminescence in the AAV8 HBD3.GFP-treatedmice was observed 24 h post-E.
coli infection, compared to AAV8 GFP treated mice, signifying reduced bacterial ascent
in AAV8 HBD3.GFP-treated mice. Furthermore, there was a significant increase in the
number of living pups in AAV HBD3.GFP-treated mice. We propose that HBD3 may
be a potential candidate for augmenting cervical innate immunity to prevent ascending
infection-related preterm birth and its associated neonatal consequences.
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INTRODUCTION
Preterm birth, defined as delivery before 37 completed weeks
gestation, affects 11% of pregnancies worldwide (1). It is the
single largest cause of mortality in infants under 5 years old
and it is associated with serious morbidity in the surviving
infants, particularly for those born before 32 weeks gestation
(2). Prematurity accounts for 29% of global neonatal deaths
per year and for 3.1% of total disability adjusted life years in
the global burden of disease (3). Despite extensive research,
the rates of preterm birth have remained stable over the
years; this is thought to be largely due to a lack of effective
preventative treatments.
Preterm birth is a highly complex, multifactorial biological
process which culminates in the premature activation of the
common parturition pathway (4). Evidence indicates a role
for infection and inflammation in preterm birth, particularly
in those occurring before 28 weeks, and it is estimated to be
associated with up to 40% of preterm deliveries (5). In clinical
studies, the increased prevalence and diversity of intrauterine
bacterial DNA is associated with preterm pre-labor rupture
of membranes and spontaneous preterm birth (6). Bacteria
linked with preterm birth include those genera associated with
relatively low pathogenicity such as Ureaplasma, Fusibacterium,
Mycoplasma and Streptococcus (6). Once in the pregnant uterus,
bacteria interact with the mucosal lining and the local immune
system initiating an inflammatory cascade leading to cervical
ripening and myometrial contractility, ultimately resulting in
preterm parturition (7). Animal models confirm this link;
inoculation of the intrauterine cavity with live bacteria or
bacterial pattern recognition pattern (PRR) moieties, such as
lipopolysaccharide (LPS), leads to preterm birth (8, 9). In
humans, this preterm inflammatory pathway has proved resistant
to most therapies including antibiotics, cervical cerclage and
tocolytics; meta-data analysis shows that progesterone appears
to delay preterm birth, although its role in infection and
inflammation remains unclear (10).
Ascending vaginal infection is considered to be the most
common route by which bacteria gain access into the uterine
cavity in cases of spontaneous preterm birth (11). This hypothesis
is supported by the association recorded between the bacterial
species identified in the amniotic fluid, fetal membranes and
placenta and those normally found in the lower genital tract
(6, 12). Additionally, recent data suggests that dominance of
a particular bacterial species within the vaginal microbiota are
associated with an increased risk of preterm birth (13).
The ability of the human cervix to prevent bacteria ascending
from the vagina to the uterine cavity depends on several
factors, including a mucus plug that provides a negatively-
charged platform for interaction with cationic antimicrobial
peptides (AMPs) including the constitutively expressed human
β-defensins-1 (14, 15). It is not known why certain women
develop ascending infection; women who have had previous
cervical excisional treatment are associated with an increased
risk of preterm birth (16), but it is likely that an endogenous
Abbreviations: PTB, preterm birth; HBD-3, human β-defensin-3.
compromise in cervical mucosal immunity plays a key role in
these cases (17). In support of this, recent evidence has shown an
association between PTB and low mid-trimester cervico-vaginal
levels of human β-defensin 2 (18).
HBDs, produced by the cervical epithelium, critical for
maintaining mucosal host-microbial homeostasis (19). In
addition to their direct microbicidal role against pathogens,
they mediate inflammation by influencing cytokine production,
immune cell chemotaxis and epithelial cell proliferation (20).
Human β-defensin 3 (HBD3) has potent and broad-spectrum
antimicrobial activity against bacteria, fungi, and viruses (21,
22). Possessing multiple positively charged arginine and lysine
residues it has the highest net positive charge of all AMPs
which probably contributes to its broad-spectrum action. Its
antimicrobial activity is not affected by differing physiological
salt concentrations, making it an ideal choice for a clinical
treatment (21). Furthermore, HBD3 binds to bacterial products,
such as LPS, resulting in reduced pro-inflammatory cytokine
responses (23).
The transfer and expression of therapeutic genes in the context
of cervical mucosa has been explored as a potential treatment
for infectious diseases. For example, anti-HIV antibodies have
been delivered using an adeno-associated viral vector (AAV) to
human cervical and vaginal cells in vitro and also to the lower
genital tract of rhesus macaques to successfully prevent mucosal
acquisition of HIV infection in vivo (24, 25). Gene transfer to the
murine cervix, however, has not been described before, although
the use of adenoviral vectors to deliver specific pro-inflammatory
cytokines to the mouse vagina has been explored as a possible
treatment for vaginal candidiasis (26).
The objectives of our present study were to evaluate the
function of the HBD3 gene, delivered to the cervix using AAV8,
in a mouse model of ascending infection-related preterm birth.
We have previously established an ascending infection-model
of preterm birth using bioluminescent E. coli K1 A192PP-lux2
(E. coli K1) (27, 28), a strain known to cause neonatal sepsis
and meningitis in rats. In this model, E. coli K1 administration
induced delivery significantly earlier than in pregnant mice
receiving intravaginal PBS as well as leading to a significant
reduction in the proportion of pups born alive compared with
intravaginal PBS controls (28).
Here, we tested the hypothesis that cervical gene expression
of HBD3 reduces microbial ascension into the pregnant uterine
cavity, reducing the frequency of preterm birth.
MATERIALS AND METHODS
Viral Vector Production
The following viral vectors were used in this study; AAV2/8,
VSV-g pseudotyped lentivirus, recombinant adenovirus serotype
5. The vectors carried the firefly luciferase or enhanced GFP
transgene under the control of the cytomegalovirus (CMV)
promoter. Lentiviral vectors were gifted from Dr. Stephen Howe
(University College London, UK). The adenoviral vectors were
gifted from Dr. Alan Parker (Cardiff University, UK). The AAV
viral vectors were developed and purchased from Vector Biolabs
(Malvern, USA).
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An AAV8 bicistronic vector encapsidating a single-stranded
DNA sequence containing the HBD3 gene (Vega Sanger
HBD3 transcript VEGA68:CM000670.2) under the transcription
activity of the CMV promoter, followed by the eGFP gene under
the transcription activity of a further CMV promoter, and BGH
polyA downstream from theHBD3 and eGFP gene was generated
(Vector Biolabs, Malvern, USA) (Supplementary Figure 1).
Animals and Treatments
All animal studies were conducted under UKHomeOffice license
70/8030 and approved by the UCL Ethical Review Committee.
C57BL/6N-Tyrc−Brd mice were obtained from the Charles
River Laboratory (Oxford, UK) and adult mice (6–12 weeks) were
time mated. The following morning (when a vaginal plug was
noted) was designated as embryonic day 0.5.
Animal Injections
Adult (6–8 weeks old) female C57BL/6N-Tyrc−Brd mice were
anesthetized with isoflurane in 100% oxygen. Ten microliter of
virus (diluted in PBS if necessary) to a concentration of 1 ×
1012 genomic copies/mL was administered intravaginally using
a 200 µl sterile pipette tip. This was applied in combination
with 20 µl of AK12 thermosensitive pluronic gel (PolySciTech,
Indiana, U.S.A)
For pregnancy experiments, vector was administered as
described above on embryonic day 13.5.
Ascending Vaginal Infection Model
The ascending vaginal infection model was developed using
E. coli K1 A192PP modified to contain the lux operon from
Photorhabdus luminescens (E. coli K1 A192PP-lux2). Twenty
microliter of mid-logarithmic-phase E. coli (1 × 102 E. coli
K1 A299 resuspended in 10mM phosphate buffer), or 20 µl
of phosphate-buffered saline (PBS) in control animals, was
delivered into the vagina of pregnant mice anesthetized with
isoflurane using a 200-ml pipette tip on embryonic day 16.5.
Following bacterial administration, mice were placed in
individual cages and continuously monitored with individual
closed-circuit television cameras and a digital video recorder
(29). Time to delivery was recorded and defined as the number
of hours from the time of bacterial administration to delivery of
the first pup. The number of live and dead pups were recorded.
Living pups were weighed daily and were culled if there was a
10% loss in body weight (in accordance with PPL 70/8030).
Whole-Body Bioluminescence Imaging
Adult mice were anesthetized with isoflurane in 100% oxygen.
Neonatal mice (up to postnatal day 6) remained conscious
during imaging (30). Mice were imaged using a cooled charged-
coupled device camera (IVIS machine, Perkin Elmer, Coventry,
UK) for between 1 s and 5min. The regions of interest (ROI)
were measured using Living Image Software (Perkin Elmer) and
expressed as photons per second per centimeter squared per
steradian (photons/second/cm2/sr).
Tissue Collection
Non-pregnant mice were sacrificed 72 h after viral vector
administration. Pregnant mice were sacrificed 18 and 24 h
after intravaginal infection. Mice were anesthetized using
isoflurane, the right atrium incised, and PBS injected into the
left ventricle for exsanguination. Uterine tissue was stored in
4% paraformaldehyde. Embryos were stored in 10% neutral-
buffered formalin. A separate cohort of mice were sacrificed
by cervical dislocation and vagina, cervix, uterus, placenta,
and fetal membranes were collected and stored at −20◦C for
protein analysis.
Storage of Fixed Cervical and Vaginal
Tissues
Cervical and vaginal tissues were stored in 4% PFA for 48 h,
transferred to 30% sucrose at 4◦C then 40µm transverse sections
obtained using a microtome. Embryos were stored in 10%
neutral-buffered formalin for 48 h, followed by storage in 70%
ethanol before paraffin embedding and sectioning at 5 µm.
Ex vivo Luminometry
Tissue samples were lysed with 500 µl of 1x Lysis buffer
(Promega) followed by homogenisation. The homogenates were
centrifuged for 10min at 18,000 g and the supernatants collected.
Each sample was loaded on to a white 96 well plate. 1.5mM
of luciferase (Promega) was added at a 1:1 volume ratio to the
sample. A FluoStar Omega microplate reader (BMG labtech) was
used to read the luminescence and the results were analyzed using
MARS data analysis data software (BMG labtech).
HBD3 Enzyme-Linked Immunosorbent
Assay (ELISA)
HBD3 concentrations in vaginal lavage was measured by ELISA
(PeproTech, London, UK) per manufacturer’s instructions.
Results were read using the FluoStar Omega microplate reader
and analyzed in MARS data analysis data software. The cross-
reactive non-specific background from the ELISA was not
subtracted from our analysis so that others repeating the ELISA
have some measure of the degree of background.
GFP Immunohistochemistry and
Co-localization Immunofluorescence
Representative sections of the organ were selected, mounted
onto double-coated chrome gelatin Superfrost slides (VWR,
Leicestershire, UK) and left to dry. The slides were placed in 4%
PFA for 10min followed by washing in TBS (1x Tris-buffered
saline). They were treated with 30% H2O2 in TBS for 30min
at room temperatures and then blocked with 15% normal goat
serum (Vector Laboratories, Peterborough, U.K.) in 0.1% TBS-T
(0.1% of Triton X-100 in 1x TBS) for 30min at room temperature.
This was followed by incubation in primary anti-GFP antibody
(Abcam, Cambridge, U.K.) in 10% normal goat serum in 0.1%
TBS-T overnight at 4◦C. The slides were washed and secondary
antibody (Abcam, Cambridge, U.K.) in 10% serum in 0.1% TBS-
T was added for 2 h at room temperature. Following this the
slides were incubated for 2 h in ABC Vectastain (Vector Labs,
Peterborough, UK). Slides were transferred into DAB solution
(0.05% 3.3′-diaminobenzidine (DAB) in TBS with 30%H2O2 and
left for 2 to 3min. The slides were air dried, dehydrated in 100%
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ethanol and placed in Histoclear (National diagnostics, USA),
followed by cover slipping with DPX mounting solution.
A similar protocol was followed for co-localization
immunofluorescence staining; slides were incubated in two
primary antibodies (in 10% normal goat serum in 0.1% TBS-T);
anti-GFP antibody (Abcam, Cambridge UK) and anti-pan
cytokeratin antibody (Abcam, Cambridge, UK) or anti-HBD3
antibody (Abcam, Cambridge, UK). This was followed by
incubation with two corresponding Alexafluor secondary
antibodies (Abcam, Cambridge, U.K.) in 10% normal goat
serum in 0.1% TBS-T. Sections were then incubated with DAPI
for 2–3min and then washed in TBS. The sections were dried
away from direct sunlight and then coverslips mounted using




Neutrophil immunohistochemistry was performed using the
same protocol to GFP immunohistochemistry above; with
primary rat anti-Ly6g antibody and Goat anti-rat secondary
antibody (Abcam, Cambridge, U.K.).
Cervical sections were visualized using a x5 objective lens and
the epithelium and sub-epithelial stromal areas were identified.
Five random fields of view were selected using a x40 objective
lens. The numbers of neutrophils were counted per area. Three
to five sections were counted per mouse and the number of
neutrophils counted per area averaged per mouse.
E. coli Immunofluorescence
Formalin-fixed embryos were paraffin embedded and sectioned.
Paraffin embedded slides were placed in Histoclear for 10min
and then rehydrated in ethanol. Antigen retrieval was then
performed by boiling the slides in citrate buffer for 20min
followed by washing in 1xTBS. Slides were blocked with
15% normal goat serum in 0.1% TBS-T for 30min at room
temperature. This was followed by incubation in primary rabbit
anti-E. coli antibody (Abcam, Cambridge, U.K.) in 10% normal
goat serum in 0.1% TBS-T overnight at 4◦C. The slides were
washed and secondary Goat anti-rabbit IgG H&L Alexa Fluor R©
488 (Abcam, Cambridge, U.K.) antibody in 10% serum/ 0.1%
TBS-T was added for 2 h at room temperature. Following this
the slides were incubated for 2 h in ABC Vectastain (Vector
Labs, Peterborough, UK). Slides were transferred into DAB
solution (0.05% DAB/30% H2O2/TBS) and left for 2–3min. The
slides were air dried, dehydrated in 100% ethanol and placed
in Histoclear (National diagnostics, USA), followed by cover
slipping with DPX mounting solution.
E. coli Killing Assays
Escherichia coli K1 was grown to mid-logarithmic phase and
diluted to 1 × 105 colony forming units(CFU)/ml. The
bacteria were centrifuged at 14,000 g for 3min. The pellet was
washed once in 10mM phosphate buffer followed by further
centrifugation and re-suspension in 10mM phosphate buffer. In
a 96 well plate, 90 µl of the resuspended bacteria was mixed with
90 µl vaginal lavage or 10mM phosphate buffer. The plate was
incubated for 30 mi at 37◦C. Twenty microlitre of each sample
was then mixed with PBS (to inhibit further AMP activity). Serial
dilutions were then plated and placed at 37◦C overnight. CFUs
were counted the following morning.
Cervical Inflammatory Cytokine Analyses
by Quantitative PCR
A cohort of cervices initially collected at 72 h post viral vector
administration (as detailed above) were stored in RNAlater
at −80◦C for quantitative PCR (qPCR) analysis. Total RNA
was extracted using the RNeasy mini kit (Qiagen, UK), as
per the manufacturer’s guidelines. Total RNA was reverse
transcribed with the High Capacity cDNA Reverse Transcription
kit (Applied Biosystems, USA). Primer sets were obtained
from Life Technologies (Supplementary Table 1) and qPCR was
performed in the presence of SYBR green. Target gene expression
was normalized for RNA loading by using GAPDH, using the
2−11Ct method of analysis. All qPCR analyses were performed
on an Applied Biosystems QuantStudio 3 instrument (Applied
Biosystems, USA).
Bacterial DNA Extraction
Bacterial DNA extraction from frozen vaginal lavage samples
was done using Qiagen spin protocol as per manufacturer’s
instructions with an additional bead beating step (Qiagen DNA
mini kit, Denmark).
16S DNA Sequencing
The DNA from the above step was quantified using a Qubit
DNA high sensitivity assay kit and Qubit 2.0 machine (Thermo
Fisher Scientific, UK). The DNA concentration in each well was
normalized to the lowest concentration sample. The DNA was
then pooled including negative DNA extraction controls. This
library was diluted to 0.4 nM after quantification using the Qubit
2.0, standard curve qPCR and an Agilent high sensitivity DNA kit
with the Agilent 2200 Tapestation instrument (Agilent genomics,
Santa Clara, US). Library preparation was carried out using dual-
indexed forward and reverse primers, with barcodes. Library
preparation PCR was performed. The resulting amplicon was
cleaned and pooled using AMPure XP beads (Beckman Coulter)
as per manufacturer’s instructions. Each plate was pooled into an
equimolar final library after quantification using a Qubit 2.0 (Life
technologies). Library was loaded onto a MiSeq (Illumina) as per
manufacturer’s protocol for 500 cycle V2 kits with the addition of
custom sequencing primers for read 1, read 2 and index 1. Data
was analyzed using QIIME software (v1.8.0).
Statistics
Data are expressed as means ± SEM. Time-to-delivery data
were log-transformed before analysis, and the proportion of live
born pups was arc-sin transformed before analysis. Data were
analyzed by unpaired t-tests, one-way ANOVAs and two-way
ANOVAs (with post-hoc Bonferroni tests). All statistical analyses
were performed with GraphPad Prism software version 7.0. P <
0.05 was considered statistically significant.
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RESULTS
A Murine Model of Ascending Bacterial
Infection and Preterm Birth
The murine model of infection was essentially as described
previously by our laboratory (28). The ability of a pathogenic
strain of E. coli K1 A192PP-lux2 (E. coli K1) to ascend into
the embryonic day 16.5 pregnant uterine cavity was investigated
(28). Bioluminescence imaging of the dam revealed ascent of
bacteria to the top of the uterine cavity by 24 h (Figure 1A), with
diffuse spread of bacteria in the fetal membranes, the placenta
and the amniotic fluid by 18 h (Figure 1B). By 24 h bacteria were
evident in the fetus (Figure 1C); immunoperoxidase staining
for bacteria revealed microbial presence within the respiratory
and gastro-intestinal (GI) tract (Figure 1D). By postnatal day 1
(∼72 h post-infection), bacteria were predominantly seen in the
GI tract (Figure 1E).
Selection of Viral Vector for Optimal Gene
Transfer to the Cervical Mucosa
To determine if viral vectors are capable of delivering genes to
the cervical mucosa, separate cohorts of non-pregnant adult mice
received intravaginal delivery of either adeno-associated virus
serotype 2/8 (AAV8), recombinant adenovirus serotype 5 (rAD5)
andVSVg pseudotypedHIV lentivirus, each containing the firefly
luciferase transgene. Luciferase expression was seen in the lower
genital tract 48 to 120 h after vector administration (Figure 2A).
Although there was high luciferase activity from VsVG pseudo-
typed HIV lentivirus, AAV was chosen for the ensuing studies
due to its relatively low immunogenicity, episomal-nature,
thermostability and success in numerous clinical trials (31–33).
Following AAV8 administration, it was confined to the upper
vagina and cervix at 72 h with no spread to the uterus or
liver (Figures 2B,C). This vector was used for the remaining
experiments due to its relatively low immunogenicity and success
in a wide range of pre-clinical and clinical trials (31, 34).
Specific Location of Vaginal and Cervical
Protein Expression
Thermosensitive pluronic gels have been developed for
numerous functions, including vaginal drug delivery (35–37).
We assessed AK12, that gels at 30 degrees Celsius, as a method
to prolong the contact time of the vector with the epithelium to
improve transduction. Delivering AAV8 GFP in combination
with this gel intravaginally resulted in significantly higher GFP
expression than delivering vector alone (P = 0.02, Figure 2D).
This expression was co-localized with cytokeratin, a marker of
the cervical epithelial cell layers (Figure 2E). Following AAV-8
luciferase intravaginal administration bioluminescence imaging
revealed luciferase expression to behighest between 3 and 5 days
after transduction and lastingfor up to 14 days (Figure 2F).
HBD3 Expression and Function
Following intravaginal administration of AAV8 HBD3.GFP,
HBD3, and GFP expression was co-localized in the cervical
and upper vaginal epithelium after 72 h (Figure 3A). HBD3 was
detected in the vaginal lavage 96 h after vector administration,
indicating that the HBD3 peptide was appropriately synthesized
and secreted into the mouse cervix and vagina (Figure 3B).
We performed E. coli killing assays with these lavages.
A trend for increased bactericidal activity was observed in
AAV HBD3.GFP treated vs. PBS controls, but this did not
reach statistical significance (Figure 4A). Immunohistochemical
detection of neutrophils was performed on cervical tissue
72 h after AAV.HBD3 GFP, AAV.GFP and PBS intravaginal
administration (Figure 4B). This showed a significant increase
in neutrophil recruitment to the cervical epithelium layer in
the AAV8 HBD3.GFP group 72 h after vector administration,
compared with the AAV8 GFP and PBS only controls (P= 0.009
and P= 0.017, respectively, Figure 4C).
Vaginal lavage samples were taken before- and at
multiple time points after- vector or PBS administration to
investigate the effect of HBD3 on the vaginal microbiome.
Delivery of AAV8 HBD3.GFP had no effect on the
alpha diversity index (Supplementary Figure 2A) or the
distribution of bacterial classes compared to the AAV8
GFP control group was similar before and after vector
administration (Supplementary Figure 2B).
HBD3 Gene Delivery to Prevent Ascending
Infection
Next we investigated the effects of AAV8 HBD3.GFP delivery
on ascending infection and preterm birth. AAV8 HBD3.GFP or
AAV8 GFP control was administered to the vaginas of pregnant
dams on embryonic day 13.5, followed by administration of E.
coli K1 intravaginally on embryonic day 16.5. Representative
images of an AAV8 HBD3.GFP treated and AAV8 GFP
control mouse are shown in Figure 5A. AAV8 HBD3.GFP
administration resulted in significantly less uterine bacterial
bioluminescence, a marker of bacterial ascent, 24 h after bacterial
administration (embryonic day 17.5) (P = 0.0015). A similar
trend at 48 h post-bacterial administration (embryonic day 18.5)
was seen but did not reach statistical significance possibly
due to reducing levels of HBD3 expression by this time
point (P= 0.09; Figure 5B).
The reduced ascent of bacteria into the uterine cavity in the
AAV8 HBD3.GFP group led us to hypothesize that this group
would also have reduced preterm birth rates. Delivery within 48 h
(embryonic day 18.5) of intravaginal administration of E. coli K1
was considered preterm birth, whereas mice delivering after this
point was considered term. AAV8 HBD3.GFP resulted in a small,
non-significant reduction in preterm labor to 60 vs. 78% in AAV8
GFP controls (P= 0.37, Table 1).
The AAV8 HBD3.GFP group delivered significantly earlier
than the control mice not infected with bacteria (mean 50.7 h ±
11.4 vs. 65.5 h ± 6.3, P = 0.02, Figure 5C) and the mean time
of delivery was not significantly different from that of the AAV8
GFP group or the infected only group (mean 50.7 h ± 11.4 vs.
46.1± 8.0 vs. 48.81± 6.2, P= 0.99, Figure 5C).
AAV HBD3.GFP treatment significantly increased the
proportions of live pups, vs. AAV8 GFP controls (0.86 vs. 0.54,
respectively (Figure 5D), Unpaired t-test; P = 0.028) but did not
increase survival rates at 7 days (AAV8 HBD3.GFP 60.3% vs.
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FIGURE 1 | Intravaginal bioluminescent Escherichia coli K1 A192PP-lux2 (E. coli K1) can ascend into the pregnant uterine cavity and induce premature delivery (30).
(A) Pregnant mice received intravaginal E. coli K1 on embryonic day 16.5, bacteria ascend into the uterine cavity over 24 h. (B) At 18 h after E. coli K1 administration
bacteria is seen specifically within the pregnant uterine cavity and is detected in the fetal membranes, the placenta and the amniotic fluid by 18 h. (C) By 24 h, bacteria
is detected in the fetus. (D) Immunohistochemical detection of E. coli in the fetus shows E. coli specifically within the lung alveoli and small intestine at 24 h, whilst no
E. coli is seen in the uninfected fetus (sections counterstained with haematoxylin), n = 3, Scale bar 40µm. (E) By Postnatal day 1 (72 h after infection), E. coli is clearly
seen in the Gastrointestinal tract.
AAV8 GFP 55.9%, P = 0.2; Figure 6A). However, there was a
small non-significant increase in survival in those pups born at
term in the AAV8HBD3.GFP group (85.2 vs. 62.5%, respectively,
P = 0.16, Figure 6B).
DISCUSSION
Despite recent advances in preterm birth research, current
therapies do not appear to have an impact on preterm birth rates
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FIGURE 2 | Gene delivery to the cervix is possible using viral vectors. (A) Adenovirus-associated virus-8 (AAV-8), Recombinant adenovirus 5 (rAd5), VSVg lentiviral
vectors can deliver luciferase to the cervix resulting in transient luciferase expression. (B,C) 72 h following AAV8-CMV-f.luc administration, luciferase expression is
limited to the cervix and upper vagina, n = 3. ****P < 0.0001, data were analyzed by a 1-way ANOVA with post-hoc Bonferroni test. Gene transfer to the cervix using
AAV 8 viral vector is improved when delivered with the pluronic gel, AK12, and results in transient protein expression in the epithelial cell layers. (D) Cervical GFP
expression is increased when AAV8 GFP is delivered in combination with AK12, compared with AAV8 GFP delivery alone, n = 3. *P < 0.05, data were analyzed by a
unpaired T-test. (E) GFP expression is detected in the epithelial layers of the cervix, confirmed by protein co-localization with cytokeratin expression. Scale bar 20µm.
(F) Following delivery of AAV8-CMV-f.luc in combination with AK12 gel, luciferase expression in the cervix lasted for up to 14 days, with peak expression occurring
between 3 and day 5, n = 3.
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FIGURE 3 | Cervical delivery of the AAV8 HBD3.GFP vector results in HBD3 peptide expression in the epithelial layers of the cervix and upper vagina and is secreted
into the vaginal fluid. (A) Upper vaginal and cervical tissue were harvested 72 h after vector or PBS administration. HBD3 and GFP are detected in the cervix and
vagina following AAV HBD3.GFP administration, n = 3. Scale bar 20µm. (B) Vaginal lavage was collected from a different cohort of mice 72 h after administration of
the vector or PBS, n = 3. *P < 0.05, data were analyzed by an unpaired T-test. The cross-reactive non-specific background from the ELISA was not subtracted from
our analysis.
(38). Approximately 40% of preterm births are thought to be
associated with infection, specifically ascending infection from
the vagina and despite this knowledge, prophylactic antibiotics
have not be shown to alter preterm birth rates (39). Here,
we show that a localized cervical treatment, which delivers
an endogenous human gene with antimicrobial properties, can
reduce ascending infection in pregnant mice and lead to an
increase in neonatal survival.
We show that gene delivery to the murine cervix is possible
using common viral vectors and is augmented by the use of
thermosensitive pluronic gel. In contrast to the human cervix,
the entirety of the murine cervix comprises stratified squamous
epithelium (40). Although little is known about the mouse cervix,
we do know that one layer of the 28-layer human vaginal and
ectocervical stratified squamous epithelium sheds every 4 h (41)
and so pluronic gels may improve transduction efficiencies by
increasing contact time of vector with epithelium. Pluronic gels
have previously been used in combination with adenovirus vector
to deliver VEGF to the uterine circulation as a treatment for fetal
growth restriction (42). The benefits of these gels are that they
are biodegradable, low in toxicity and they transfer from aqueous
phase to gel phase on increasing temperature. Furthermore, there
is evidence that pluronic gels help to facilitate cervico-mucus plug
penetration without comprising the function of the barrier (43).
AAV8 HBD3.GFP did not significantly increase the
gestational length in E. coli K1 infected dams. However,
there was an increase in the proportion of pups born alive from
dams in this group with a tendency toward increased 7 day
survival rates for neonates born at term following E. coli K1
infection. There was no increase in preterm pup survival in the
first week of life, however, suggesting that pups delivered early are
more susceptible to E. coli K1 infection. Although E. coli is not
classically associated with preterm birth, it has commonly been
used to induce preterm birth in animal models. The pathogenic
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FIGURE 4 | AAV8 HBD3.GFP increases neutrophil recruitment to the upper cervical epithelial layers. (A) Escherichia coli killing assays were performed on vaginal
lavages from AAV8 HBD3.GFP, AAV8 GFP, and PBS treated mice. There was no difference in bacterial kill, n = 3. Data were analyzed with a 1-way ANOVA and
post-hoc Bonferroni tests. (B) Representative images of cervical neutrophil localization using immunohistochemical staining of Ly-6g with haematoxylin counterstain.
Brown coloration depicts DAB-positive cells, Scale bar 20µm. (C) Neutrophil numbers in cervical epithelial cell layers were increased following AAV8 HBD-3
transduction, compared with AAV8 GFP (P = 0.009) and PBS (P = 0.02); AAV8 GFP vs. PBS (P = 0.99), n = 3. *P < 0.05, **P < 0.01, data were analyzed with a
1-way ANOVA and post-hoc Bonferroni tests.
strain used in this study, E. coli K1 strain A192PP, like group B
streptococcus, is responsible for causing neonatal meningitis in
humans which is dependent on vertical transmission from the
mother44. In preterm birth, the bacteria identified include a wide
array notable for relatively low levels of pathogenicity such as
Ureaplasma spp. and Mycoplasma spp6. Experiments performed
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FIGURE 5 | Delivery of AAV8 HBD3.GFP reduces bacterial ascent into the pregnant uterine cavity and increases the proportion of pups born alive. (A) An example of
an AAV8 HBD3.GFP treated mouse and an AAV8 GFP treated mouse 24 h after bacterial administration. (B) Marked difference in uterine bacterial bioluminescence in
mice treated with AAV8 HBD3.GFP, compared with AAV8 GFP, n = 10 at 24 h (P = 0.009); n = 4 at 48 h (P = 0.09); smaller sample size as postnatal dams were
excluded. **P < 0.01, data were log-transformed and analyzed with unpaired t-tests due to sample size differences at the 2 time points. (C) The AAV8 HBD3.GFP
group delivered significantly earlier than the control mice not infected with bacteria (PBS only) and the mean time of delivery was not significantly different from that of
the AAV8 GFP group or the infected only group, n = 8–10. *P < 0.05, **P < 0.01, data were log transformed and analyzed with a one-way ANOVA and post hoc
Bonferroni tests. (D) There was an increase in the proportion of pups born alive in the AAV8 HBD3.GFP treated group, compared with the AAV8 GFP group, n = 10.
*P < 0.05, data were arc-sin transformed and analyzed with an unpaired test.
TABLE 1 | Ascending infection-induced preterm birth rates: preterm birth rates





AAV8 GFP 78% 9
Data analyzed with Fisher exact test.
by our group using non-pathogenic E. coli K12 do indeed show
reduced bacterial ascent into the uterine cavity following cervical
HBD-3 therapy, however, this model does not induce preterm
birth in mice (unpublished data) (28).
The mechanisms by which cervical HBD3 reduces bacterial
ascent into the uterine cavity is uncertain. Although HBD3
is known for its potent antimicrobial action, we were unable
to measure a statistical difference in the microbicidal activity
of the vaginal lavage from AAV8 HBD3.GFP vs. AAV8 GFP
treated mice in the experimental time frame. Microbicidal
activity has only been detected previously in the ng-µg/ml
range (21), however our supplementary data shows some E.
coli killing activity at pg/ml (shown in Supplementary Figure 3)
and so it is unlikely that the pg/mg levels detected here are
insufficient to lead to some direct antibacterial activity in vivo.
It is possible, however, that the killing assays using the HBD3
peptide obtained from the lavage sample did not show any direct
killing activity due to the instability of these peptides in bodily
fluids due to peptidase degradation (44, 45). Interestingly, within
the same time frame, the presence of HBD3 resulted in an
increase in neutrophil influx into the cervical epithelium in vivo.
Therefore, it is likely that HBD3-mediated bacterial clearance
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FIGURE 6 | There is no difference in pup survival over the first week of life
between AAV HBD3.GFP and AAV GFP pups, although there is a trend for
increased survival in the term AAV HBD3.GFP pups compared with AAV GFP
controls pups. (A) Overall pup survival over the first week of life (all pups were
culled on Day 7). (B) Term pup survival over the first week of life (all pups were
culled on Day 7). Term pups were defined as those that were delivered > 48 h
after bacterial administration. n = 53 in the AAV HBD3.GFP group, n = 27 in
AAV GFP group (Term pups; AAV HBD3.GFP n = 23, AAV GFP n = 10). Data
analyzed by Log-rank Mantel-Cox test.
involves activation of multiple antimicrobial mechanism(s). A
study looking at the benefits of exogenously delivered human
cathelicidin LL-37 in a murine model of Pseudomonas aeruginosa
lung infection found that cathelicidin LL-37 enhanced bacterial
clearance in vivo (46). The authors similarly found no evidence
of a direct microbicidal effect and it was concluded that the likely
mechanism of bacterial clearance is peptide-mediated enhanced
early neutrophil influx. Our observations also support a crucial
role for HBD3-driven neutrophil influx, taken together, it is
tempting to suggest that neutrophil mediation may present a
significant armory of AMP action.
The HBD3 levels detected at a single time point in the vaginal
lavage are incredibly small following freeze drying of the lavage
(∼200 pg/mg protein). In the literature only levels in the ng-
µg/mg protein range from transfected cells in vitro have been
detected on western blot (47, 48). This may be primarily be
due to species variation and/or due to the experimental setup
of our current study e.g., cervicovaginal samples were taken
96 h following gene transfer whilst bioluminescence (indicative of
HBD3 gene expression) continued up to 120 h post-gene delivery
(Figure 2A). Future experiments, exploring dose-response and
time course of expression will be valuable for providing
further insight into HBD3 production. Cervicovaginal levels of
endogenousmouse defensin peptides were not assessed, however,
our unpublished data suggests a trend toward reduced Defb14
(the gene for mBD14, the mouse ortholog of HBD-3) mRNA
levels in the AAV8HBD-3 treated cervices. Further studies would
need to be conducted to assess the level of mouse defensin
peptides within the cervico-vaginal fluid.
Recent data has shown that human cervical mucus plugs
contain at least 28 AMPs, although interestingly, the AMPs
were at insufficient concentrations to have antimicrobial activity
against Group B streptococcus, a bacteria commonly implicated
in preterm birth (49). However, these AMP appear to have a
role in amplifying the immune response including enhanced
leucocyte activity and complement-mediated killing. In support
of this, emerging evidence suggests that HBDs have a much
more complex role in the immune system than being solely
endogenous antimicrobials, they have previously been shown
to recruit immune cells, such as neutrophils, macrophages,
and dendritic cells (50, 51). In contrast to our findings here,
HBD3 has previously been reported to have direct chemotactic
activity on human monocytes and not neutrophils (51). The
chemotactic activity onmurine neutrophils seen in this study and
its mechanism, direct or indirect, needs to be elucidated in future
studies. Neutrophils are critical effector cells and form part of
the first line of defense against microorganisms. HBD2 has been
shown to attract neutrophils via the G-protein phospholipase
C-dependent pathway (50). The cysteine residues of the three
disulphide bridge structure of HBD3 appear to be necessary for
this chemotactic role (52). In addition to its chemotactic role,
HBD3 has been shown to prolong the lifespan of neutrophils at
sites of infection by preventing apoptosis (53). The molecular
mechanism(s) involved in HBD3-mediated neutrophil influx in
our model system require further investigation.
During human pregnancy, a rise in estrogen levels leads
to a stable vaginal microbiome dominated by Lactobacillus
species (54). Lactobacillus are thought to inhibit pathogen growth
by secreting antimicrobial bacteriocins as well as producing
lactic acid which helps to maintain a low acidic pH (55). The
composition of the vaginal microbiota appears to be closely
associated with preterm birth outcome (13, 56). Mice treated
with either AAV8 HBD3.GFP or AAV8 GFP did not show
significant changes in their vaginal microbiota nor did it modify
Lactobacillus species abundance in the vagina (data not shown).
This is not surprising given the limited bactericidal activity seen
in the lavage samples (likely as a result of insufficient levels of
HBD3) and so it is likely the microbiota system is stable to minor
fluctuations. We know that in human pregnancy, the vaginal
microbiota becomes less diverse and more stable despite the
hormonal and immunological changes associated with pregnancy
(57). Furthermore, sampling 7 days following gene therapy may
be an insufficient time course for detection of change as a
previous study looking at the effects of stress show differences
> 14 days later (58). In support of our findings, HBD3 does not
exhibit antibacterial activity against lactic acid bacteria, including
L. rhamnosus, suggesting that these bacteria may exhibit factors
that protect them from host immune defense (59). Recent data
indicates an association between an L.iners-dominant vaginal
microbiome and an increased risk of preterm birth, whilst
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L.crispatus-dominance appears to be protective (13). L.crispatus
promotes epithelial cell defense against Candida albicans in vitro
by increasing HBD levels, in particular, HBD3 (60). This finding
may play a role in linking themechanism of L.crispatus-dominant
vaginal microbiome with its protective effect on preterm birth.
HBD3 was previously considered to be pro-inflammatory as
its expression increases following TLR activation or IL-1β, TNF-
α and IFN-g release (21, 51), however, emerging data recognizes
it more as amultifunctional effector of the immune system (61). It
is possible that HBD3 may induce a strong chemoattractant and
inflammatory response at high concentrations during infection
and injury to respond to the insult whilst at lower concentrations
it has anti-inflammatory and healing properties (62). In
this study, we found no evidence of increased inflammatory
cytokine expression in the cervical tissue at 72 h following gene
transfer of AAV.HBD3 GFP compared with AAV GFP but
further time course expression analyses may show differences
(Supplementary Figure 4). Further studies would also need to be
conducted to assess for other surrogate markers of inflammation
or cytotoxicity, such as NF-kB activation, particularly as HBD-
3 has been found to be overexpressed in cases of cervical
cancer (63). In the GI tract, HBD3 plays an important role in
contributing to mucosal immune tolerance (64). As the vaginal
microbial composition appears to be so closely related to preterm
birth risk, HBD3 expression in the cervix may also improve
immune tolerance to certain commensal bacteria.
The use of antimicrobial gene therapy has been explored
previously, mainly as a way of treating infections with antibiotic
resistant bacteria and treating certain wound infections where
the skin epithelium has been severely damaged, such as
burns (65). Gene delivery of HBD3 to keratinocytes using
adenoviral vectors has been performed in studies investigating
novel treatments for wound infections (66, 67). In an in
vivo porcine model of infected diabetic wounds, adenoviral
vectors delivering HBD3 resulted in reduced bacterial load 4
days after vector administration and an improvement in re-
epithelialization of the wound (66). The wound healing role
of HBD3 may also be of interest in women at high risk of
preterm birth who have had previous cervical treatment for
high risk precancerous cervical lesions. In particular, HBD3 is
shown to promote skin re-epithelialization, granulation tissue
formation and collagen I deposition. In preterm birth, premature
remodeling, and shortening of the cervix involves degradation
of cervical stromal collagen, particularly collagen I and III,
by matrix metalloproteinases (68–70). Therefore, HBD3 gene
therapy could help to inhibit this process by encouraging collagen
I deposition.
Preterm birth remains a major global health problem, being
responsible for greater than a million neonatal deaths per
year (71). Despite the employment of current preventative
strategies for preterm birth, there has been no decline in preterm
birth rates highlighting the importance of further research into
novel therapies (72). The use of HBD3 in augmenting cervical
mucosal immunity may have a role in reducing the intra-uterine
inflammation associated with ascending vaginal infection-related
preterm birth and warrants further studies to explore its potential
for clinical translation.
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58. Jašarević E, Howard CD, Misic AM, Beiting DP, Bale TL. Stress during
pregnancy alters temporal and spatial dynamics of the maternal and
offspring microbiome in a sex-specific manner. Sci. Rep. (2017) 7:44182.
doi: 10.1038/srep44182
59. Wang XF, Tian F, Cao RM, Li J, Wu SM, Guo XK, et al. Antimicrobial
activity of human β-defensins against lactic acid bacteria.Nat Prod Res. (2015)
29:2164–6. doi: 10.1080/14786419.2014.996754
60. Rizzo A, Losacco A, Carratelli CR. Lactobacillus crispatusmodulates epithelial
cell defense against Candida albicans through Toll-like receptors 2 and 4,
interleukin 8 and human β-defensins 2 and 3. Immunol Lett. (2013) 156:102–9.
doi: 10.1016/j.imlet.2013.08.013
61. Semple F, MacPherson H, Webb S, Cox SL, Mallin LJ, Tyrrell C, et al.
Human beta-defensin 3 affects the activity of pro-inflammatory pathways
associated with MyD88 and TRIF. Eur J Immunol. (2011) 41:3291–300.
doi: 10.1002/eji.201141648
62. Boughan PK, Argent RH, Body-Malapel M, Park JH, Ewings KE, Bowie AG,
et al. Nucleotide-binding oligomerization domain-1 and epidermal growth
factor receptor: critical regulators of beta-defensins during Helicobacter
pylori infection. J Biol Chem. (2006) 281:11637–48. doi: 10.1074/jbc.
M510275200
63. Xu D, Zhang B, Liao C, Zhang W, Wang W, Chang Y, et al.
Human beta-defensin 3 contributes to the carcinogenesis of cervical
cancer via activation of NF-κB signaling. Oncotarget. (2016) 7:75902–13.
doi: 10.18632/oncotarget.12426
64. Meisch JP, Nishimura M, Vogel RM, Sung HC, Bednarchik BA, Ghosh
SK, et al. Human β-defensin 3 peptide is increased and redistributed in
crohn’s ileitis. Inflamm Bowel Dis. 19:942–53. doi: 10.1097/MIB.0b013e318
280b11a
65. Jacobsen F, Mittler D, Hirsch T, Gerhards A, Lehnhardt M, Voss B, et al.
Transient cutaneous adenoviral gene therapy with human host defense
peptide hCAP-18/LL-37 is effective for the treatment of burn wound
infections. Gene Ther. (2005) 12:1494–502. doi: 10.1038/sj.gt.3302568
66. Hirsch T, Spielmann M, Zuhaili B, Fossum M, Metzig M, Koehler T, et al.
Human beta-defensin-3 promotes wound healing in infected diabetic wounds.
J Gene Med. (2009) 11:220–8. doi: 10.1002/jgm.1287
67. Carretero M, Del Río M, García M, Escámez MJ, Mirones I, Rivas L, et al.
A cutaneous gene therapy approach to treat infection through keratinocyte-
targeted overexpression of antimicrobial peptides. FASEB J. (2004) 18:1931–3.
doi: 10.1096/fj.04-1515fje
68. Gonzalez JM, Franzke CW, Yang F, Romero R, Girardi G. Complement
activation triggers metalloproteinases release inducing cervical
remodeling and preterm birth in mice. Am. J. Pathol. (2011) 179:838–49.
doi: 10.1016/j.ajpath.2011.04.024
69. Kirby MA, Heuerman AC, Custer M, Dobyns AE, Strilaeff R, Stutz KN,
et al. Progesterone receptor–mediated actions regulate remodeling of the
cervix in preparation for preterm parturition. Reprod Sci. (2016) 23:1473–83.
doi: 10.1177/1933719116650756
70. Sundtoft I, Langhoff-Roos J, Sandager P, Sommer S, Uldbjerg N. Cervical
collagen is reduced in non-pregnant women with a history of cervical
insufficiency and a short cervix. Acta Obstet Gynecol Scand. (2017) 96:984–90.
doi: 10.1111/aogs.13143
71. Lawn JE, Gravett MG, Nunes TM, Rubens CE, Stanton C. Global report on
preterm birth and stillbirth (1 of 7): definitions, description of the burden and
opportunities to improve data. BMC Pregnancy Childbirth. (2010) 10(Suppl
1):S1. doi: 10.1186/1471-2393-10-S1-S1
72. Martin JN, D’Alton M, Jacobsson B, Norman JE. In pursuit of progress
toward effective preterm birth reduction. Obstet Gynecol. (2017) 129:715–9.
doi: 10.1097/AOG.0000000000001923
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Suff, Karda, Diaz, Ng, Baruteau, Perocheau, Taylor, Alber,
Buckley, Bajaj-Elliott, Waddington and Peebles. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Immunology | www.frontiersin.org 14 February 2020 | Volume 11 | Article 106
